Abstract library

50 results for "register".
#1536 Merkel Cell Carcinoma – Epidemiology Data from the Czech National Cancer Registry
Introduction: Merkel cell carcinoma (MCC) is rare and aggressive neuroendocrine tumor. The incidence is increasing worldwide, most probably due to population aging (mostly in the Western Europe), higher rates of sun exposure, immunosuppression and other not well defined epigenetic changes.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD,PhD Viera Bajciova
Authors:
#1200 Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Data from the German NET-Register
Introduction: Everolimus (EVE) has importantly impacted the treatment (Tx) of mostly pancreatic NEN.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Authors:
Keywords: everolimus, outcome
#1201 Results of Sunitinib Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Outcome Data from the German NET-Register
Introduction: Among modern treatments (Tx) for neuroendocrine neoplasms (NEN) sunitinib (SUN) has impacted Tx of primarily pancreatic NEN (pNEN).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Authors:
Keywords: sunitinib, outcome
#1648 Treatment Patterns and Survival Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden – A Population-Based Register-Linkage and Medical Chart Review Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a group of neoplasms derived from the endocrine system in the GI tract and pancreas.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Åse Björstad
Authors:
#107 Results of the Gastroenteropancreatic NETs Spanish Registry in the 2001-2010 period
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are infrequent and heterogeneous neoplasms that have conditioned the lack of verified epidemiologic data.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Jaume Capdevila
Authors:
#389 Czech Neuroendocrine Tumor Registry - 28 Months Results
Introduction: Cooperative Group for NET was established on 22 April 2008. It continues with the practices of the Czech Carcinoid Group since 1998. The real incidence of neuroendocrine tumors is unknown. The majority remain undiagnosed. Therefore, the Czech Registry started in October 2009 to identify NET patients and to facilitate the diagnosis and therapy in centers with NET experts.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Jaroslava Barkmanova
Authors:
#1657 Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System
Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D., Ph.D. Toshihiko Masui
Authors:
#1365 Exploring the Rising Incidence of Gastroenteropancreatic Neuroendocrine Tumors According to the Data from Regional Cancer Registry: A Population-Based Analysis of Epidemiology
Introduction: The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is reported to arise worldwide. Similar tendency is observed in Bulgaria during the recent 6 years.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Paulina Vladova
Authors:
#1484 Neuroendocrine Tumors of the Appendix Are Probably Harmless Neoplasms
Introduction: Appendiceal neuroendocrine tumors (aNETs) have a 5-year survival rate between 74% and 95% according to recent data from Cancer Registry of Norway and the United States, respectively. However, in the daily clinical practice one almost never encounters patients suffering from aNETs with distant metastasis or dying of the disease.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Maike Nieser
Authors:
Keywords: NET
#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan
Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kazuhiro Toriyama
Authors:
Keywords: prop-up, japan, gep-nen